---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277914"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:40:17.577240+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies stockholders approve doubling authorized common stock to 400M shares

## Summary
- Special meeting on Nov 15, 2023: 72.16% of shares represented; amendment passed with 133,386,292 votes for.
- Authorized shares increased from 200,000,000 to 400,000,000 via Certificate of Amendment filed with Delaware.
- Only 1,370,285 votes against and 157,132 abstained out of 134,913,709 shares voted.

## SEC filing metadata
- accession: 0001193125-23-277914
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277914/0001193125-23-277914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277914/d941656d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277914
- JSON: https://secwatch.observer/filing/0001193125-23-277914.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277914.txt

## Key facts
- Governance Changes
  Taysha Gene Therapies, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2023-11-15).
  - Change: charter amendment
  - Effective: 2023-11-15
  source text: On November 15, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended to date, to increase the authorized number of shares of the Company’s common stock from 200,000,000 shares to 400,000,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277914/0001193125-23-277914-index.htm
- Shareholder Votes
  Taysha Gene Therapies, Inc. shareholders approved Approval of an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. at the 2023-11-15 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-11-15
  source text: Proposal No. 1: Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company's common stock from 200,000,000 to 400,000,000. The votes were cast as follows: Votes For Votes Against Abstained Amendment to effectuate an authorized shares increase 133,386,292 1,370,285 157,132
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277914/0001193125-23-277914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.